Article
The predictive and prognostic role of phosphatase phosphoinositol-3 (PI3) kinase (PIK3CA) mutation in HER2-positive breast cancer receiving HER2-targeted therapy: a meta-analysis.
Breast cancer research and treatment - 1 Aug 2015
Ibrahim Ezzeldin M, Kazkaz Ghieth A, Al-Mansour Mubarak M, Al-Foheidi Meteb E
Abstract excerpt
The association between PIK3CA mutation and resistance to anti-HER2 therapy (AHT) is not precisely defined. This meta-analysis intended to explore the clinical utility of PIK3CA mutation in HER2-positive breast cancer treated with AHT. Literature search identified 19 eligible studies. There were 1720 patients with advanced, 828 with early and 1290 patients treated in the neoadjuvant setting. In metastatic breast...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.